SharecloseShare pageCopy linkAbout sharing

The first new treatment for Alzheimer’s disease for nearly 20 years has been approved by regulators in the United States, paving the way for its use in the UK.

Aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia, rather than its symptoms.

At least 100,000 people in the UK with a mild form of the disease could be suitable for the drug.

But approval from the UK regulator could take more than a year.

Charities have welcomed the news.

The US Food and Drug Administration (FDA) said there was “substantial evidence that aducanumab reduces amyloid beta plaques

This story is from The BBC News. To read the full story, please go to https://www.bbc.co.uk/news/health-57383763.

This post was originally published on this site